Zantac / Ranitidine (NDMA Cancer) Attorney in Philadelphia, Pennsylvania

Zantac Litigation in Philadelphia

Philadelphia's Court of Common Pleas Mass Tort Program is one of the most experienced pharmaceutical litigation venues in the country. Pennsylvania applies a modified Frye / Pa.R.E. 702 standard for expert admissibility that has been interpreted in ways potentially more favorable than strict federal Daubert for novel causation claims. Philadelphia's mass tort bar is nationally recognized and includes several firms with Zantac coordination experience. Philadelphia-area claimants may file in Philadelphia CCP or coordinate in Delaware Superior Court. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Resources for Philadelphia Zantac Claimants

Philadelphia-area Zantac claimants should obtain pharmacy records from Rite Aid (Philadelphia-area concentration), CVS, Walgreens, and Giant/Stop & Shop pharmacies. Medical records from Penn Medicine, Jefferson Health, or Fox Chase documenting cancer diagnosis, staging, and treatment are essential. Pennsylvania's 2-year SOL applies from the discovery of the cancer diagnosis and its potential link to Zantac/NDMA exposure.